| abstract |
The present invention relates to novel crystalline forms of the sodium salt of (4- {4- [5- (6-trifluoromethyl-pyridin-3-ylamino) -pyridin-2-yl] -phenyl} -cyclohexyl) - acetic acid, and their use in the treatment or prevention of a disease state or disorder associated with DGAT1 activity in animals, particularly humans. The invention also relates to methods of making such new crystalline forms. |